Metsera Inc. (NASDAQ:MTSR - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Metsera in a note issued to investors on Tuesday, July 29th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($3.48) for the year, down from their prior estimate of ($3.45). Cantor Fitzgerald also issued estimates for Metsera's FY2026 earnings at ($3.95) EPS.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.
MTSR has been the topic of a number of other research reports. Wells Fargo & Company started coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera has a consensus rating of "Buy" and a consensus price target of $55.00.
View Our Latest Analysis on Metsera
Metsera Stock Down 1.3%
Shares of Metsera stock traded down $0.47 on Thursday, reaching $34.42. 670,978 shares of the company were exchanged, compared to its average volume of 950,087. Metsera has a one year low of $12.30 and a one year high of $47.40. The firm's 50-day moving average is $32.59.
Institutional Investors Weigh In On Metsera
A number of large investors have recently added to or reduced their stakes in MTSR. Alphabet Inc. bought a new stake in Metsera in the 1st quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. bought a new stake in Metsera in the 1st quarter valued at $78,748,000. Wellington Management Group LLP bought a new stake in Metsera in the 1st quarter valued at $65,382,000. Alpha Wave Global LP acquired a new position in Metsera in the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in Metsera in the 1st quarter valued at $42,395,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access